Telomir Pharmaceuticals Raises $5.6M via PIPE Financing for Cancer Research

Key Facts

1Telomir Pharmaceuticals announced an approximately $5.6 million private investment in public equity (PIPE) financing.

2Billionaire entrepreneur and existing shareholder John Paul DeJoria invested an additional $1.0 million in the financing.

3The financing consists of common stock only, without any accompanying investor warrants or convertible securities.

Telomir Pharmaceuticals announced an approximately $5.6 million private investment in public equity (PIPE) financing. GlobeNewswire reported that the financing consists of common stock only, without any accompanying investor warrants or convertible securities. The company intends to use the proceeds primarily to support the clinical development of Telomir-Zn, specifically for its Phase 1/2 clinical program in patients with advanced or metastatic triple-negative breast cancer.

Billionaire entrepreneur and existing shareholder John Paul DeJoria invested an additional $1.0 million in this financing round. TELO closed at $1.21 on October 5, 2026, having traded between a day low of $1.19 and a high of $1.27 during that session. This capital raise is directed toward advancing the company's small-molecule therapeutics targeting cancer drivers while maintaining a non-dilutive structure regarding warrants.